Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptic Ulcer Disease I: Introduction01:30

Peptic Ulcer Disease I: Introduction

139
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
139
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

74
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
74
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

303
Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.
303
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

356
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
356
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

362
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
362
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

91
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
91

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Does Treatment of <i>Helicobacter pylori</i> Infection Pose a Risk to Patients With GERD?

Gastroenterology & hepatology·2026
Same author

Gastric cancer secondary prevention in dyspeptic patients.

Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association·2026
Same author

Physiologically Based Pharmacokinetic Modeling and Simulation to Support a Change in the FDA-Labeled Dosing Frequency of RHB-105 Low-Dose Rifabutin Triple Therapy for Helicobacter pylori Eradication.

Journal of clinical pharmacology·2025
Same author

Endoscopic Diagnosis, Grading, and Treatment of Bleeding Peptic Ulcer Disease.

Gastrointestinal endoscopy clinics of North America·2024
Same author

Developments in Gastroesophageal Reflux Disease over the Last 40 Years.

Digestive diseases (Basel, Switzerland)·2023
Same author

Helicobacter pylori World Gastroenterology Organization Global Guideline.

Journal of clinical gastroenterology·2023

Related Experiment Video

Updated: Jun 9, 2025

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

6.6K

Peptic Ulcer Disease: A Review.

Nimish Vakil1

  • 1University of Wisconsin School of Medicine and Public Health, Madison.

JAMA
|October 28, 2024
PubMed
Summary

Peptic ulcer disease, caused by H. pylori or NSAIDs, affects many. Treatment involves acid blockers and eradicating H. pylori, significantly reducing recurrence.

Area of Science:

  • Gastroenterology
  • Internal Medicine
  • Epidemiology

Background:

  • Peptic ulcer disease (PUD) affects 1% of the US population, with 54,000 annual hospitalizations for bleeding.
  • Upper abdominal pain in primary care is often caused by PUD.
  • Key causes include Helicobacter pylori (42%) and NSAID use (36%).

Purpose of the Study:

  • To summarize the epidemiology, causes, complications, diagnosis, and treatment of peptic ulcer disease.
  • To highlight the effectiveness of current treatments in healing ulcers and preventing recurrence.

Main Methods:

  • Literature review and synthesis of epidemiological data on PUD prevalence, causes, and outcomes.
  • Analysis of treatment efficacy for PUD, including acid suppression, H. pylori eradication, and NSAID management.

More Related Videos

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

977
Author Spotlight: Point-of-Care Ultrasound for Gastric Content Assessment and Risk Stratification in Perioperative Care
05:50

Author Spotlight: Point-of-Care Ultrasound for Gastric Content Assessment and Risk Stratification in Perioperative Care

Published on: September 22, 2023

2.6K

Related Experiment Videos

Last Updated: Jun 9, 2025

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management
06:40

The Dyspepsia Educational Tool As a Novel Aid in Dyspepsia Management

Published on: June 29, 2019

6.6K
Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors
03:05

Author Spotlight: Advancing Early Detection and Treatment of Gastrointestinal Tumors

Published on: February 16, 2024

977
Author Spotlight: Point-of-Care Ultrasound for Gastric Content Assessment and Risk Stratification in Perioperative Care
05:50

Author Spotlight: Point-of-Care Ultrasound for Gastric Content Assessment and Risk Stratification in Perioperative Care

Published on: September 22, 2023

2.6K

Main Results:

  • PUD complications include bleeding (73%), perforation (9%), and obstruction (3%), with 10,000 annual deaths in the US.
  • Proton pump inhibitors (e.g., omeprazole) heal 80-100% of ulcers within 4-8 weeks.
  • H. pylori eradication reduces recurrence from 50-60% to 0-2%; discontinuing NSAIDs heals 95% of ulcers and reduces recurrence from 40% to 9%.

Conclusions:

  • PUD is a significant cause of morbidity and mortality.
  • Proton pump inhibitors are the primary treatment for healing ulcers.
  • Preventing recurrence involves H. pylori eradication and judicious NSAID use or co-therapy.